ARS Pharmaceuticals, Inc.
SPRY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671858
Insider trades, last 90 days
None
- No open-market purchases or sales were filed in the last 90 days.
13F holders, Q2 2026
208
- +5 vs. Q1 2026
- Total value $726.68M
Superinvestors holding SPRY
1
- At the end of Q2 2026
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by SPRY insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Jun 12, 2026 | Karas EricChief Commercial Officer | SSaleCommon Stock | −25K | $10.00 | −$250K | 12.18K | −67.2% | SEC10b5-1 |
| Jun 12, 2026 | Jun 12, 2026 | Fitzpatrick Alexander AChief Legal Officer | SSaleCommon Stock | −3.36K | $10.00 | −$33.55K | 90.91K | −3.6% | SEC10b5-1 |
| Nov 14, 2025 | Nov 12, 2025 | Chakma JustinChief Business Officer | SSaleCommon Stock | −166.38K | $8.869 | −$1.48M | 0 | −100.0% | SEC |
| Nov 14, 2025 | Nov 13, 2025 | Dorsey BrianChief Operating Officer | SSaleCommon Stock | −21.83K | $8.71 | −$190.12K | 10.79K | −66.9% | SEC |
| Aug 22, 2025 | Aug 21, 2025 | Lowenthal Richard EPRESIDENT AND CEO | SSaleCommon Stock | −50K | $14.49 | −$724.5K | 1.2M | −4.0% | SEC10b5-1 |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in SPRY at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10,860,977 | $87M | 0.76% | 00.0% | Unchanged |
| Rubric Capital Management LP | 8,540,861 | $68.41M | 0.63% | +540,861+6.8% | Added |
| ORBIMED ADVISORS LLC | 8,288,510 | $66.39M | 1.26% | 00.0% | Unchanged |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 7,503,812 | $60.11M | 0.63% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,311,319 | $42.54M | 0.00% | +299,065+6.0% | Added |